Lonza Peptides

Lonza Peptides is the U.S. division of Lonza Group, one of the world's most respected global pharmaceutical and biotechnology contract development and manufacturing organizations (CDMOs). Operating out of Portsmouth, NH, this facility stands as a cornerstone of large-scale GMP peptide and oligonucleotide production for clinical and commercial drug development. With decades of parent-company expertise behind it, Lonza Peptides brings enterprise-level pharmaceutical manufacturing capabilities to the North American market, serving drug developers who require rigorous quality standards and reliable production at scale.

As a leading peptide manufacturer, Lonza Peptides offers an extensive range of contract manufacturing services designed to support pharmaceutical and biotech clients from early clinical stages through full commercial launch. The Portsmouth facility specializes in the synthesis, purification, and formulation of complex peptides and oligonucleotides under current Good Manufacturing Practice (cGMP) conditions. Among manufacturers in this specialized space, Lonza Peptides is recognized for handling high-complexity molecules at both clinical and commercial volumes, making it a trusted partner for organizations seeking a fully integrated peptide manufacturer capable of scaling alongside their drug development programs.

Within the broader peptide industry, Lonza Peptides occupies a prominent position as part of a globally recognized CDMO network. The Portsmouth, NH operation extends Lonza Group's worldwide manufacturing footprint into the U.S. market, offering national reach to pharmaceutical companies, biotechnology firms, and drug sponsors across the country. Whether clients are sourcing for investigational new drug (IND) filings or commercial supply agreements, this facility is positioned to support projects at a national scale, connecting American drug developers to world-class peptide manufacturing infrastructure without the logistical complexity of offshore sourcing.

For industry professionals evaluating peptide manufacturers, quality and regulatory compliance are paramount considerations. The Portsmouth facility operates as an FDA-inspected site and maintains ISO certification, reflecting a commitment to the highest standards expected of pharmaceutical-grade manufacturers. Professionals sourcing from established manufacturers should prioritize documented quality systems, demonstrated regulatory inspection history, and the capacity to produce materials that meet pharmacopeial and ICH guidelines. Lonza Peptides exemplifies the type of rigorously compliant manufacturing environment that clinical researchers and pharmaceutical sponsors require when selecting a long-term CDMO partner.

Industry professionals, drug developers, and procurement teams looking for a trusted peptide manufacturer in Portsmouth with the backing of a global pharmaceutical CDMO are encouraged to connect with Lonza Peptides directly. Whether your organization requires feasibility assessments, process development support, or large-scale commercial manufacturing, the team at Lonza Peptides is equipped to discuss partnership opportunities tailored to your program's specific needs. Reaching out early in your development timeline allows for a more seamless integration of manufacturing planning with your regulatory and clinical strategy.